Lytix Biopharma
Norway - OsloPharmaceutical
Focus: Lytix Biopharma is a Norwegian public-stage biotech specializing in oncolytic peptides for oncology and antimicrobial indications. The company operates as a focused pipeline player with multiple Phase 1/2 programs across cancer and infectious disease.
Profile data last refreshed 13h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
0
About Lytix Biopharma
AI assessmentNot HiringNo open roles listed right now. Follow Lytix Biopharma to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
9 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
LTX-315
CarcinomaClinical Trials (1)
NCT01223209A Study, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma
Phase 1Help build intelligence for Lytix Biopharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.